These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38184576)

  • 1. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey.
    Palis H; Haywood B; McDougall J; Xavier CG; Desai R; Tobias S; Burgess H; Ferguson M; Liu L; Kinniburgh B; Slaunwhite AK; Crabtree A; Buxton JA
    Harm Reduct J; 2024 Jan; 21(1):5. PubMed ID: 38184576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
    Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motivators of and barriers to drug checking engagement in British Columbia, Canada: Findings from a cross-sectional study.
    Tobias S; Ferguson M; Palis H; Burmeister C; McDougall J; Liu L; Graham B; Ti L; Buxton JA
    Int J Drug Policy; 2024 Jan; 123():104290. PubMed ID: 38101275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada.
    Papamihali K; Yoon M; Graham B; Karamouzian M; Slaunwhite AK; Tsang V; Young S; Buxton JA
    Harm Reduct J; 2020 Nov; 17(1):90. PubMed ID: 33228676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating opioid preference to inform safe supply services: A cross sectional study.
    Ferguson M; Parmar A; Papamihali K; Weng A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Mar; 101():103574. PubMed ID: 35007878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia.
    Kamal A; Ferguson M; Xavier JC; Liu L; Graham B; Lock K; Buxton JA
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):27. PubMed ID: 37194018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada.
    Klaire S; Janssen RM; Olson K; Bridgeman J; Korol EE; Chu T; Ghafari C; Sabeti S; Buxton JA; Lysyshyn M
    Int J Drug Policy; 2022 Aug; 106():103741. PubMed ID: 35671687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada.
    Moshkforoush M; DeBeck K; Brar R; Fairbairn N; Cui Z; Milloy MJ; Buxton J; Oldenburger T; McLellan W; Kendall P; Sedgemore K; Wilson D; Kerr T; Hayashi K
    Harm Reduct J; 2022 May; 19(1):50. PubMed ID: 35614440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving towards a continuum of safer supply options for people who use drugs: A qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada.
    Foreman-Mackey A; Pauly B; Ivsins A; Urbanoski K; Mansoor M; Bardwell G
    Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):66. PubMed ID: 36209227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do we understand the value of drug checking as a component of harm reduction services? A qualitative exploration of client and provider perspectives.
    Moran L; Ondocsin J; Outram S; Ciccarone D; Werb D; Holm N; Arnold EA
    Harm Reduct J; 2024 May; 21(1):92. PubMed ID: 38734643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overdose Prevention and Housing: a Qualitative Study Examining Drug Use, Overdose Risk, and Access to Safer Supply in Permanent Supportive Housing in Vancouver, Canada.
    Ivsins A; MacKinnon L; Bowles JM; Slaunwhite A; Bardwell G
    J Urban Health; 2022 Oct; 99(5):855-864. PubMed ID: 36044156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site.
    Kolla G; Tarannum CN; Fajber K; Worku F; Norris K; Long C; Fagundes R; Rucchetto A; Hannan E; Kikot R; Klaiman M; Firestone M; Bayoumi A; Laurence G; Hayman K
    Harm Reduct J; 2024 Jan; 21(1):17. PubMed ID: 38243267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Awareness, predictors and outcomes of drug alerts among people who access harm reduction services in British Columbia, Canada: findings from a 2021 cross-sectional survey.
    Daowd K; Ferguson M; Liu L; Loyal J; Lock K; Graham B; Lamb J; McDougall J; Buxton JA
    BMJ Open; 2023 May; 13(5):e071379. PubMed ID: 37160395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feeling safer: effectiveness, feasibility, and acceptability of continuous pulse oximetry for people who smoke opioids at overdose prevention services in British Columbia, Canada.
    Moe J; Chavez T; Marr C; Cameron F; Feldman-Kiss D; Wang YE; Xavier JC; Mamdani Z; Purssell RA; Salmon A; Buxton JA
    Harm Reduct J; 2024 Feb; 21(1):45. PubMed ID: 38378610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motivations for concurrent use of uppers and downers among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey.
    Steinberg A; Mehta A; Papamihali K; Lukac CD; Young S; Graham B; Lock K; Fleury M; Buxton JA
    BMJ Open; 2022 May; 12(5):e060447. PubMed ID: 35501101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations with experience of non-fatal opioid overdose in British Columbia, Canada: a repeated cross sectional survey study.
    Ferguson M; Choisil P; Lamb J; Burmeister C; Newman C; Lock K; Tobias S; Liu L; Buxton JA
    Harm Reduct J; 2023 Dec; 20(1):178. PubMed ID: 38093272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative changes in illicit drug supply during COVID-19: Associations with use of overdose prevention and health services among women sex workers who use drugs (2020-2021).
    Moreheart S; Shannon K; Krüsi A; McDermid J; Ettinger E; Braschel M; Goldenberg SM
    Int J Drug Policy; 2023 Nov; 121():104212. PubMed ID: 37797570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia.
    Mema SC; Sage C; Popoff S; Bridgeman J; Taylor D; Corneil T
    Harm Reduct J; 2018 Apr; 15(1):19. PubMed ID: 29625621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with 60-day adherence to "safer supply" opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency.
    Selfridge M; Card K; Kandler T; Flanagan E; Lerhe E; Heaslip A; Nguyen A; Moher M; Pauly B; Urbanoski K; Fraser C
    Int J Drug Policy; 2022 Jul; 105():103709. PubMed ID: 35525052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "If it wasn't for them, I don't think I would be here": experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis.
    Kolla G; Pauly B; Cameron F; Hobbs H; Ranger C; McCall J; Majalahti J; Toombs K; LeMaistre J; Selfridge M; Urbanoski K
    Harm Reduct J; 2024 Jun; 21(1):111. PubMed ID: 38849866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.